Filing Flows › X4 Pharmaceuticals (XFOR) › Q2 2026 › vs Q1 2026
X4 Pharmaceuticals (XFOR) Q2 2026 vs Q1 2026 (quarter over quarter)
X4 Pharmaceuticals's revenue fell $100K (-4%) from $2.5M in Q1 2026 to $2.4M in Q2 2026. The biggest changes: Revenue from contracts with customers +$6.1M (+225%).
X4 Pharmaceuticals, Q2 2026: revenue $2.4M (+41% year over year), operating margin -683.0%, net loss $16.2M, operating cash flow −$20.8M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| License and other revenue | $6.4M | $239K | $6.2M | 27× |
| Product revenue, net | $2.4M | $2.5M | −$96K | -4% |
| Revenue from contracts with customers | $8.8M | $2.7M | $6.1M | +225% |
| Revenue | $2.4M | $2.5M | −$100K | -4% |
| Other revenues (net loss) | $6.4M | $208K | $6.2M | 31× |
| Other income, net | $236K | $65K | $171K | +263% |
| Net loss | $16.2M | $20.2M | −$4.1M | -20% |
| Costs & expenses | $18.8M | $22.8M | −$4.0M | -18% |
| Operating costs | $18.8M | $22.8M | −$4.0M | -18% |
| Income tax | $2K | $0 | $2K | — |
| Operating cash sources | $24.9M | $22.2M | $2.6M | +12% |
| Depreciation & amortization | $997K | $223K | $774K | +347% |
| Share-based compensation | $3.1M | $2.4M | $673K | +28% |
| Cash used in operations | $20.8M | $19.6M | $1.2M | +6% |
| Net loss absorbed | $16.2M | $20.2M | −$4.1M | -20% |
| Working capital & other | $8.7M | $2.0M | $6.7M | +337% |
Questions
How much did X4 Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
X4 Pharmaceuticals's revenue fell $100K (-4%) from $2.5M in Q1 2026 to $2.4M in Q2 2026.
What drove X4 Pharmaceuticals's revenue change in Q2 2026?
Revenue from contracts with customers +$6.1M (+225%).